Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis

[1] Martín-Sánchez JC(2018)Projections in breast and lung Cancer mortality among women: a Bayesian analysis of 52 countries worldwide Cancer Res 78 4436-4442

[2] Lunet N(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[3] González-Marrón A(2016)The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer J Thorac Oncol 11 39-51

[4] Jemal A(2010)Non-small cell lung cancer J Natl Compr Cancer Netw 8 740-801

[5] Bray F(2011)Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities Ther Adv Med Oncol. 3 113-125

[6] Center MM(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246

[7] Ferlay J(2014)ROS1 expression and translocations in non-small-cell lung cancer: Clinicopathological analysis of 1478 cases Histopathology. 65 187-194

[8] Ward E(2012)ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 863-870

[9] Forman D(2014)Crizotinib in ROS1-rearranged non-small-cell lung cancer N Engl J Med 371 1963-1971

[10] Goldstraw P(2013)A genomics-based classification of human lung tumors Sci Transl Med 5 209ra153-135

[1] Martín-Sánchez JC(2018)Projections in breast and lung Cancer mortality among women: a Bayesian analysis of 52 countries worldwide Cancer Res 78 4436-4442

[2] Lunet N(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[3] González-Marrón A(2016)The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer J Thorac Oncol 11 39-51

[4] Jemal A(2010)Non-small cell lung cancer J Natl Compr Cancer Netw 8 740-801

[5] Bray F(2011)Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities Ther Adv Med Oncol. 3 113-125

[6] Center MM(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246

[7] Ferlay J(2014)ROS1 expression and translocations in non-small-cell lung cancer: Clinicopathological analysis of 1478 cases Histopathology. 65 187-194

[8] Ward E(2012)ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 863-870

[9] Forman D(2014)Crizotinib in ROS1-rearranged non-small-cell lung cancer N Engl J Med 371 1963-1971

[10] Goldstraw P(2013)A genomics-based classification of human lung tumors Sci Transl Med 5 209ra153-135